.INVESTIGATION HIGHLIGHT.16 Oct 2024. In the NIAGARA hearing, the add-on of perioperative durvalumab to regular treatment for muscle-invasive bladder cancer boosted event-free and generally survival, marking a new procedure choice for this ailment.
Universal Insights Knowledge Hub
Hub for knowledge on universal insights covering news, finance, technology, health, and lifestyle.
.INVESTIGATION HIGHLIGHT.16 Oct 2024. In the NIAGARA hearing, the add-on of perioperative durvalumab to regular treatment for muscle-invasive bladder cancer boosted event-free and generally survival, marking a new procedure choice for this ailment.